Press Release
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
Completion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets Read More
Press Release
Prolocor(R) Announces Publication in Circulation: Cardiovascular Interventions. Results Demonstrate That the Prolocor pFCG(TM) Test Predicts Risk of Subsequent Cardiovascular Events Regardless of Treatment Strategy (Percutaneous Coronary Intervention or Medical Management Alone)
Despite differences in characteristics and treatment, the pFCG test distinguished risk of the primary ischemic endpoint to a similar extent in the 2 groups. No significant association was observed between pFCG and risk of bleeding. Read More
Press Release
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA In dogs undergoing chemotherapy, as is the case with people undergoing cancer treatment, diarrhea is a highly neglected and unmet medical need Read More
Press Release
Nixxy's Revenues Commence via Auralink AI
Successful Integration: Nixxy integrates newly acquired telecom AI software into its Auralink AI telcom subsidiary Immediate Revenue Impact: Auralink AI is expected to generate initial revenue of $250,000 for March, and $2 million in April 2025 Strategic Vision: Management strategically positions Auralink AI for expansion, delivering innovative, AI-powered billing and LCR solutions to the Communications Platform as a Service (CpaaS) industry Read More
Press Release
Interactive Strength Inc. (Nasdaq:TRNR)'s FORME Named an Exclusive Wellness Partner for Virgin Atlantic's New Clubhouse at LAX
Partnership Raises FORME's Visibility with Affluent Customers, Highlights Brand's Seamless Integration into Premium Hospitality and Travel Environments Installation adds to Hospitality Customers such as Four Seasons, Bulgari and Mandalay Bay Resort Read More
Press Release
Amaze Partners with Empact to Unlock $707.9B EU E-Commerce Market for Creators, Eliminating Surprise Fees and Expanding Global Reach
Partnering with Empact removes key barriers, allowing creators to focus on what they do best - creating - while their fans in the EU enjoy a seamless, hassle-free shopping experience. Read More
Press Release
Your Credit Score, Your Rights: Clearing Up the Misconceptions
Credit score myths often go unquestioned, leading many to accept them as facts. However, widely held beliefs about this important financial concept can be misleading. Understanding the truth is the first step toward reclaiming your financial health. Read More
Press Release
Email Marketing Integration in 2025: Key Benchmarks & Expert Guide by Selzy
Selzy, an email marketing platform, has released new research highlighting the crucial role of email marketing integrations in optimizing marketing strategies, enhancing personalization, and driving customer engagement. Read More
Press Release
United Chargers Announces Full Integration and Multi-App Capability for Grizzl-E EV Charging Stations With ev.energy
In the next step in advancing EV Charging technology, United Chargers is adding another software option to its popular Grizzl-E Ultimate product line with ev.energy. Customers now have even more choices to select software that works better for their needs and ensures long-term flexibility and peace of mind with OCPP. Read More
Press Release
Candid Health Successfully Completed a Type 1 SOC 2 Examination With an Unqualified Opinion
Candid Health Reports on Security, Availability, and Confidentiality Standards Established by The American Institute of Certified Public Accountants (AICPA) for its Candid Health Revenue Cycle Automation Platform. Read More
Press Release
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium Late-breaker abstract recently submitted to the Multinational Association of Supportive Care in Cancer (MASCC) shows additional significant results for breast cancer subgroup The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025, and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022 Read More
Press Release